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Pancreatic cancer is the fourth leading cause of cancer death in the United States, with a 
five-year survival rate under 5%. Given the disease’s deadliness, increasing our 
understanding of the molecular nature of the pancreatic cancer is key to developing more 
effective preventive measures and treatments. Dietary energy restriction (DER) has been 
shown to have potent anticancer effects in pancreatic cancer, but the mechanism of action 
has yet to be completely elucidated. Here we investigate the potential of altered 
microRNA expression as a mechanism by which DER exerts its anticancer effect. Using 
the Exiqon microRNA Array, we identified several microRNAs of interest for further 
study.  This includes microRNA (mir) 669c, a known regulator of glutathione-S 
transferases (linked to carcinogen metabolism and oxidative stress) that increases with 
age.  To our knowledge, this is the first exploration of the effects of DER (which is 
known to suppress oxidative stress and other processes associated with aging and cancer) 
on microRNA expression. These findings may provide the initial steps towards 
identifying novel targets for pancreatic cancer prevention or treatment.   
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Chapter 1:  Introduction 
In spite of its low rate of occurrence, pancreatic cancer is the fourth leading cause of 
cancer related death in the United States, with a five-year survival rate below 5%  [1].  The 
deadliness of pancreatic cancer is in large part due to the difficulty of detecting the disease early 
and effectively treating it, particularly in the later stages when the disease is typically found.  The 
inherent difficulty of early detection of pancreatic tumors means that upwards of 80% of all 
pancreatic cancer cases are diagnosed with metastases already present.  This takes away the best 
treatment option, surgical resection of the tumor, which has a five-year survival of 20%[2] The 
low five-year survival of both surgical resection and other treatment options for pancreatic 
cancer helps to highlight its resilience in the face of current treatment options and the need for 
improved therapies, and particularly, prevention strategies.  
 Improving treatment and/or prevention options for pancreatic cancer depends on 
obtaining a better understanding of the molecular nature of the disease. Though much etiologic 
research on pancreatic tumorigenesis to date has been conducted in vitro, there is also a need for 
the development of relevant in vivo models to gain a better understanding of the disease.  This 
will facilitate the development and assessment of novel treatments in a preclinical setting. For 
the purposes of our studies, we utilized a syngeneic transplant mouse model using NB508 and 
JC101 mouse pancreatic adenocarcinoma cell lines in wild-type FVB/N mice.  The rationale 
behind the use of a pancreatic adenocarcinoma model is that adenocarcinomas account for 85% 
of all neoplasms in the pancreas, and thus represent the chief concern among tumors of the 
pancreas[3]. The NB508 line is derived from the Kras/INK4A transgenic mouse, which 
possesses a mutant K-ras and a heterozygous deletion for INK4A.  These two genes are the most 
commonly altered in spontaneous human pancreatic adenocarcinoma, with K-ras activating 
2 
 
mutations present in ~85% of pancreatic tumors and INK4A deletions present ~80% of the time 
[2]. The JC101 line is derived from a K5.COX-2 transgenic mouse in which cyclooxygenase 
(COX)-2 is overexpressed in the pancreas under the keratin 5 promoter. The K5.COX-2 
transgenic mouse serves as a model for inflammation-associated pancreatic cancer, specifically 
pancreatitis induced pancreatic adenocarcinoma [4]. Though the cell lines chosen have been used 
both in vitro and in vivo in the past, neither has been used in a subcutaneous transplant model.  
 Risk factors for pancreatic cancer include advanced age, smoking, chronic pancreatitis, 
diabetes, and obesity, with advanced age being the most significant [5]. Obesity is associated 
with a two-fold increased risk for an individual with a body mass index above 35 [6]. Better 
characterization of the obesity-pancreatic cancer association is of critical importance for 3 
reasons:  1) other than smoking, obesity is the only other known modifiable risk factor for 
pancreatic cancer; 2) the growing obesity epidemic in America and throughout the world means 
it is likely that the number of cases of pancreatic cancer due to obesity will increase [7]; and 3) 
the fact that obesity enhances pancreatic cancer development suggests that examination of the 
link between obesity and pancreatic cancer could yield insight into the molecular targets and 
strategies for preventing or controlling this disease 
 In the context of energy balance (the biological homeostasis of energy in living systems), 
obesity represents a chronic surplus intake of calories relative to calories expended, which results 
in fat deposition and an alteration in serum hormones and growth factors associated with energy 
balance, cell proliferation and cell survival [8]. While obesity leads to a serum profile that 
promotes cellular proliferation, dietary energy restriction (DER) leads to a serum profile that is 
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consistent with reduced cellular proliferation and cell number homeostasis (Table 1).  
 
Table 1:  Hormonal regulators of cell proliferation according to energy balance 
 
DER is a dietary regimen that typically provides 70% of the calories but 100% of all 
micronutrients relative to an ad libitum-fed control group.  The DER regimen thus prevents or 
reverses obesity without inducing malnutrition.  In addition to preventing obesity and altering 
serum hormone profiles, DER has also proven in animal studies to be an effective tool to combat 
carcinogenesis [9]. In carcinogen-induced models of pancreatic cancer, DER was shown to 
suppress tumor formation [10], although the relevance of the carcinogen model is unclear.  Dr. 
Lashinger of the Hursting lab has performed studies showing that DER decreases the severity 
and number of pancreatic ductal lesions in K5.COX2 transgenic mice when compared to the 
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control (Fig.1). Though energy balance modification is known to affect carcinogenesis, a 
complete understanding of the mechanisms involved has yet to be obtained. 
 
Figure 1: Histological analysis of pancreatic ductal lesion in BK5.COX-2 transgenic mice shows 
that DER Protect from the formation of pancreatic lesions when compared to pancreas from 
BK5.COX-2 mice on control diet. Pancreata were also scored for inflammation, nuclear atypia 
all of which were reduced in BK5.COX-2 mice DER when compared to control diet.  
 
 Despite their growing importance in regulating translation, the role of microRNAs 
(miRNA) in the anti-cancer effects brought about by DER are unknown. First discovered in C. 
elegans, microRNAs (miRNAs) are small non-translated RNA molecules with an average length 
of twenty-two nucleotides. Initially believed to be a novel finding confined to worms, interest in 
them began in earnest with the identification of let-7 miRNA as well as the observations that is 
phylogenetically conserved. In the decade following identification of let-7, more than 700 human 
miRNA genes have been identified and their importance as posttranscriptional regulators of gene 
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expression has emerged. Current estimates have miRNA playing a role in regulating up to 30% 
of human genes involved in a range of cellular processes including: cell cycle, differentiation, 
and development [11].  
Given the scope and diversity of miRNA regulation in cells, it is not surprising that 
research has implicated abnormal miRNA profiles as a contributing factor to a host of human 
diseases, including cancer and metabolic syndrome [12, 13]. To date a number of studies have 
been performed on paraffin-embedded pancreatic tumor samples in an attempt to create a 
comprehensive list of miRNAs that are altered in pancreatic cancer. In vitro studies have 
identified a role for miRNA play in pancreatic cancer [14].  Other studies have looked at adipose 
and other tissues from obese patients who suffer from metabolic syndrome and found 
inappropriate expression profiles for miRNA. However, the relationship between altered miRNA 
expression and health problems associated with obesity, such as pancreatic cancer, has yet to be 
established. Given that improper miRNA expression plays a role in pancreatic cancer and 
metabolic alterations associated with obesity, I hypothesized that tumors in mice on DER, 
relative to ad libitum-fed controls, will exhibit favorable changes in miRNA expression that help 
to explain the DER-associated decrease in tumor burden.  The aims of this thesis project are: 
 
Specific Aims 
Aim 1. Establish the appropriateness of using a subcutaneous syngeneic transplant 
model to study the anti-cancer effects of DER. FVB mice will be placed on either a control 
diet or DER for 7 weeks prior to injection with 2x105 JC101 or NB508 cells. Following 4-weeks 
of tumor growth, mice will be killed, and tumors, blood and other tissues collected.  Endpoints 
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measured will include body weight, tumor burden, serum hormone profile, and 
immunohistochemistry (IHC). 
Aim 2. Determine changes in miRNA expression in tumors from mice on DER, 
relative to control diet. The miRNA expression of tumors from control and DER mice that 
received JC101 injection (but not the NB508 cells, which were unresponsive to DER in Aim 1 
studies) will be assessed using the Exiqon array system. Array data will be confirmed using the 
Taqman RT-PCR system for miRNA. Additionally, in vitro studies will be performed exposing 
the JC101 cell line to serum starvation and IGF-1 treatments in an attempt to identify miRNA 





Chapter 2:  Methods 
Mouse Study Design 
Upon receipt, 40 FVB mice (Charles Rivers Laboratories) were singly housed, placed on 
chow diet and allowed one week for acclimation. Following this acclimation period, mice were 
randomized to receive either the control or DER diet regimen (20 mice/diet treatment) as further 
described below in the diet manipulation portion of the methods section. Additionally, the mice 
had their body weights recorded and were given nestlets weekly for the duration of the study.  
The mice were maintained on diets for seven weeks prior to a subcutaneous injection of NB508 
or JC101 mouse pancreatic cancer cells. Following the injection of tumor cells, the mice 
remained on their respective diets and were monitored as outlined below. 
Syngeneic Subcutaneous Transplant: 
   NB508 and JC101 cells were separately suspended (in DMEM media containing 10% 
FBS) to a concentration of 2 million cells cells per ml.  Half of the mice (n=20) received a 
subcutaneous injection of 2x105 NB508 cells with the remainder receiving 2x105 JC101 cells.  
Mice were palpated biweekly for tumor formation. Upon detection of tumors, they were 
measured by electronic caliper three times/week.  Tumors grew for four weeks post-transplant 
until 50% of tumors measured greater than 1cm diameter, at which time all mice were killed.  
During euthanasia, mice were anesthetized using isoflurane.  Upon anesthetization, a cardiac 
puncture was performed as a terminal blood draw after which a cervical dislocation was 
performed.  Collected blood was allowed to sit at room temperature for thirty minutes, and then 
spun for 5 minutes at 13,000 RPM to separate serum from the blood. The serum was collected 
and placed on dry ice. Tissues collected from the euthanized mice included tumor, normal 




Upon arrival, mice (n=40) were placed on a chow diet for one week to allow for 
acclimation to the new environment.  Following acclimation, all mice were placed on the control 
diet (AIN-76A; Research Diets #D10001) for one week.  Mice were then randomized to receive 
one of two diet treatments (n=20):  1) Control Diet; or 2) 30% DER (Research Diet 
#D09071302),.  Mice remained on their respective diet for the remainder of the study (additional 
information on diets can be found in the appendix 1).  Food intake for mice placed on the AIN-
76A control diet had their food intake measured weekly in order to calculate the daily food 
allotment for the mice on 30% DER. Briefly, food intake for each singly housed mouse was 
measured by subtracting the weight of the remaining food from the initial food given. Individual 
food intake for all mice on the AIN-76A diet was used to calculate the daily food administered to 
DER mice using the following equation:  




Tumor tissue sections were fixed in 10% formalin for twenty-four hours after which the 
samples were transferred to 70% ethanol. The tumor samples were then transported to the 
histology core at M.D. Anderson Science Park where they were embedded in paraffin. In order to 
stain for CD31, slides were placed in a 60oC oven for thirty minutes. Following incubation, 
slides were deparraffinized by placing them in Hemo-De for five minutes (twice), 100% Ethanol 
for five  minutes (twice), 95% Ethanol five minutes (once), and then being rinsed under running 
water. The slides were then placed in 3% H2O2 water for ten minutes after which time they were 
rinsed in water.  Following the rinse, the slides were paped and the tissue was covered  with Tris 
buffer. The slides were then incubated in 0.06% Protease in Tris for ten minutes, after which 
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they were rinsed and then blocked in TNB buffer for thirty minutes.  The slides were then 
incubated with primary antibody using Pharmingen anti-CD31 (Clone MEC 13.3) monoclonal 
antibody. The primary antibody was diluted 1:400 in TNB buffer and then  incubated for at least 
one hour at room temperature (overnight incubation is recommended). Following primary 
antibody incubation, the slides were placed in PBS for ten minutes with T/A in preparation for a 
thirty minute incubation with the secondary antibody (Biotinlyated anti-Rat IgG) diluted at 1:200 
in TNB.  Following the secondary incubation, the slides were washed for ten minutes in PBS 
with T/A and then incubated for thirty minutes in SA-HRP diluted 1:100 in TNB buffer. The 
slides were washed again in PBS with T/A for ten minutes before incubating the slides for ten 
minutes in biotinylated tyramide (diluted 1:50 in 1x Amplification Diluent). Then the slides were 
washed again in PBS with T/A this time for fifteen minutes, incubated with SA-HRP (1:100 in 
TNB Buffer), and then washed in PBW with T/A for 10 minutes. To develop the slides Sigma 
Tablet DAB were used. During the development of the slides they were washed, counterstained, 
cleared and coversliped with a permanent mounting media.   
Ki-67 Immunohistochemistry 
To stain for Ki-67, a marker of cell proliferation, the fixed and embedded tumor tissue 
(described above) was deparaffinized in xylene and hydrated in graded alcohols (100%, 95%) to 
water. Endogenous perxoidase activity was then blocked using a wash in 3% H202 for 10 
minutes.  The slides were then washed and antigen was retieved by microwaving the samples in 
a microwave with 10mM Citrate Buffer pH 6.0 for 15 minutes (10 minutes at full power and five 
at 50%) followed by a twenty-minute cool down and wash. Next, the slides were blocked with 
non-specific antibodies by incubating them with Biocare Blocking Reagent for ten minutes. 
Following blocking, the slides were drained and incubated overnight at 4oC with primary 
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monoclonal Ki-67 antibody (Dako#M7240) at a dilution of 1:50. After incubating overnight the 
slides were washed in buffer for 5 minutes, changing the buffer once, and then incubated for 
fifteen minutes at room temperature with biotinylated rabit-anti-mouse F(ab)’  (Accurate Chem) 
at a 1:250 dilution.  The slides were then washed for five minutes in buffer, before being 
incubated with SA-HRP (BioGenex) for thirty minutes at room temperature.  Another five 
minute buffer wash was performed and the slides were incubated with Dako DAB until staining 
developed at which time the slides were washed, counterstained, dehydrated, and then 
coverslipped for viewing. 
Caspase 3 Immunohistochemistry 
 To stain for Caspase 3, tumor tissue was deparaffinized in xylene and hydrated in graded 
alcohols (100%, 95%) to water. Endogenous peroxidase activity was then blocked using a wash 
in 3% H202 for ten minutes.  The slides were then washed and antigen was retrieved by 
microwaving the samples in a microwave with 10mM Citrate Buffer pH 6.0 ten minutes 
followed by a twenty-minute cool down and wash. Next, the slides were blocked with non-
specific antibodies by incubating them with Biocare Blocking Reagent for ten minutes. Slides 
were then drained and incubated at room temperature for thirty minutes with primary Caspase-3 
polyclonal antibody (R&D AF835) at a 1:2000 dilution. Following incubation the slides were 
washed with buffer for ten minutes and then incubated for thirty minutes at room temperature 
using biotinylated goat-anti-rabbit IgG (Vector) at 1:500 dilution followed by a ten minute buffer 
wash.   The slides were then washed for five minutes in buffer, before being incubated with SA-
HRP (BioGenex) for thirty minutes at room temperature.  After another 10 minute buffer wash 
the slides were incubated with BioGenex DAB until staining developed  at which time the slides 
were washed, counterstained, dehydrated, and then coverslipped for viewing. 
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Serum Hormone Analysis  
Serum hormone analysis was performed using Milliplex Map Kits (Millipore, Buillerica, 
MS) and a Bioplex 200 system (Bio-Rad, St. Louis , MO) to measure serum levels of insulin, 
IGF-1, leptin, and adiponectin. Serum was obtained from blood collected during sacrifice of 
JC101 mice on control diet (n=10) and DER (n=9) . All procedures were performed using 
manufacturer’s instructions.    
Initial Assessment of Exiqon miRNA Array 
We had not previously used the Exiqon array system as a tool to detect changes in 
miRNA expression in our model.  Thus, a small pilot study (limited to one randomly selected 
mouse per diet treatment due to expense) was initiated to confirm the utility of this array 
platform for testing our hypothesis.  Frozen tumor and pancreas from these two mice were 
processed  using the mirVana Total RNA extraction kit as described below. Total RNA was then 
quality checked using the Agilent 2100 Expert Bioanalyzer (Agilent Technologies, Inc.; Santa 
Clara, CA) prior to running the Exiqon arrays. Four paired arrays were run with the following 
comparisons being made: 1.) Control Tumor/Control Pancreas, 2.) DER Tumor/DER Pancreas, 
3.) DER Pancreas/Control Pancreas, and 4.) DER Tumor/Control Tumor.  All arrays were run 
following the procedure described below.  
Total RNA extraction from tumor tissue  
 Following euthanasia, tumor tissue was extracted and flash frozen in liquid nitrogen and 
stored at -80oC. The extraction of RNA from tumor tissue was performed using the mirVana 
miRNA isolation kit (Applied Biosystems #AB1560). Tumor tissue was placed on dry ice 
wrapped in foil and a section of approximately 150mg was collected, diced, and placed in a 50ml 
conical tube. Additionally, lysis/binding buffer was added at ten volumes per 0.1g of tissue (1ml 
per 100mg of tissue) to the 50ml conical tube, and the samples were mechanically homogenized 
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using a Rotor-Stator homogenizer.  Following homogenization, miRNA Homogenate Additive 
was added to the samples at 1/10th volume of the added lysis/binding buffer and vortexed for 30 
seconds. Samples were placed on ice for 10 minutes and then transferred to a 15ml conical 
containing with acid phenol chloroform (volume equal to the lysate volume before addition of 
miRNA homogenate) and vortexed for 30 to 60 seconds.  The vortexed lysate/chloroform 
samples were then spun for five minutes at maximum speed and room temperature.  After 
centrifugation, the aqueous phase was carefully removed (the volume noted) and placed in a new 
15ml conical with 100% Ethanol (1.25 volumes of removed aqueous phase). The provided filter 
cartridges were placed in a collection tube and the lysate/ethanol mixture (up to 700ul) was 
pipeted in and centrifuged for ~15 seconds at no more than 10,000xG (to avoid damaging the 
filter). Following the spin, the flow through was dumped and the process repeated until all of the 
lysate/ethanol mixture had been run through the filter. After running the samples through the 
filters, a series of three washes were performed: (1) 700 ul of Wash Solution 1; (2) 500 ul of 
Wash Solution 2/3; and (3) 500 ul of Wash Solution 2/3.  Following each wash, tubes were spun 
at no more than 10,000xg for 10 seconds and the flow through was discarded. After performing 
the three washes, filter and collection tubes were spun for one minute (at under 10,000 xg) and 
the filter was transferred to a new collection tube. Finally, 100ul of 95oC nuclease-free water was 
placed on the filter, which was spun for 20-30 seconds at maximum speed. Following the spin, 
the filter cartridge was disposed of and the collected total RNA was stored at stored at -80oC. 
microRNA array of tumor tissue 
Total RNA extract from the tumor tissue of mice on DER and control diet were matched.  
The quality of the total RNA was assessed using the Agilent 2100 Expert Bioanalyzer (Agilent 
Technologies, Inc.; Santa Clara, CA). Upon confirmation of the quality, samples were labeled 
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using the Exiqon miRCURY LNA™ microRNA Power Labeling Kit (Exiqon Inc.; Woburn, 
MA).  1μg of total RNA for each sample was dephosphorylated and labeled with Hy3™ or 
Hy5™ dyes, then combined and hybridized to miRCURY LNA™ Arrays, version 15.0 (Exiqon, 
Inc.) on the TECAN HS400Pro hybridization station (Tecan US, Inc., Raleigh, NC). The control 
RNAs (so-called “spike-in”) were included in the labeling and hybridization to assist in setting 
scanner parameters. The array slides were scanned on the GenePix 4200 scanner (Axon 
Instruments; Gaithersburg, MD) and analyzed with GenePix Pro version 6.0 software (Axon 
Instruments). 
IGF-1 treatment of Panc02 cells and total RNA extraction  
Panc02 cells were grown in a T-175 flask in DMEM media with 10% FBS until 
confluent. The evening before IGF-1 treatment, Panc02 cells were trypsinized, spun down, 
washed in PBS, and resuspended in 30 ml of DMEM media with 10% FBS.  1ml of the 
resuspended Panc02 cells was added to each well in the six well plate in addition to 1 ml of 
media. The next morning all six wells were washed in PBS and incubated in serum free DMEM 
for four hours prior to treatment. The treatment groups were DMEM media with 10% FBS, 
serum free DMEM media, and 1, 2, 4 or 8 hour exposure to IGF-1(400ng/ml ,equivalent to the 
typical serum levels observed in mice consuming a control diet).  Following completion of the 
time points, the media was aspirated, wells were washed with PBS, and then trypsinized with 
1ml of trypsin for five minutes at 37oC. After incubation 1ml of DMEM media with 10% FBS 
was added to each well.  The trypsinized cells were transferred to 15ml conical tubes and spun 
down for five minutes at 1500 RPM. The media was then aspirated off and cells were 
resuspended in 1 ml of PBS, transferred to a 2ml eppendorf tubes, and spun again for five 
minutes at 1500 RPM. The PBS was aspirated and isolation of total RNA was preformed using 
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mirVana miRNA isolation kit (Applied Biosystems #AB1560). The resulting cell pellet was 
resuspended in 500ul of lysis/binding buffer and vortexed for 15seconds. 50ul of miRNA 
homogenate additive was then added to the solution, vortexed for 30 seconds, and samples were 
placed on ice for 10 minutes, and then transferred to a 15ml conical tube containing acid phenol 
chloroform (volume equal to the lysate volume before addition of miRNA homogenate) and 
vortexed for 30-60 seconds.  The vortexed lysate/chloroform samples were then spun for five 
minutes at maximum speed and room temperature. After centrifugation, the aqueous phase was 
carefully removed (volume noted) and placed in a new 15ml conical with 100% ethanol (1.25 
volumes of removed aqueous phase). The provided filter cartridges were placed in collection 
tubes and the lysate/ethanol mixture (up to 700ul) was added and centrifuged for ~15 seconds at 
no more than 10,000xg (to avoid damaging the filter). Following the spin, the flow through was 
dumped and the process repeated until all of the lysate/ethanol mixture was run through the filter. 
After running the samples through the filter, a series of three washes were performed: (1) 700 ul 
of Wash Solution 1; (2) 500ul of Wash Solution 2/3,; and (3) 500 ul of Wash Solution 2/3. 
Following each wash, tubes were spun at no more than 10,000xg for ten seconds and the flow 
through was discarded. After performing the three washes, filters and collection tubes were spun 
for one minute (at under 10,000 xg) and the filters were transferred to a new collection tube. 
Finally, 100ul of 95oC nuclease-free water was placed on the filter, which was spun for 20-30 
seconds at maximum speed. Following the spin, the filter cartridge was disposed of and the 




Reverse Transcription of Targeted microRNA from Total RNA Extract 
The concentration of total RNA collected using mirVana miRNA isolation kit (Applied 
Biosystems #AB1560) was assessed using a ND-1000 spectrophotometer (Nanodrop).  Total 
RNA samples were then diluted to a concentration of 2ng/ul in preparation for reverse 
transcription using the TaqMan MicroRNA Reverse Transcription Kit (Part # 4366596 or 
4366597). Five ul of the diluted total RNA was combined with 7ul of master mix in a 0.2ml PCR 
tube for each 15ul reaction desired to take place.  3ul of appropriate RT primer (Applied 
Biosystems) for the miRNA of interest was then added to each tube. The tubes were gently 
misted, centrifuged, and allowed to sit on ice for five minutes. Following the resting period, the 
samples were placed in a thermocycler (Eppendorf MasterCycler EP gradient S) using the 







The RT samples were stored at -20oC prior to PCR.  PCR for miRNA’s of interest was 
preformed using Taqman Probes from Applied Biosystems and Taqman Universal Master Mix 
II, no UNG (Applied Biosystems #4440043). Each PCR reaction requires 10ul of the master mix, 
7.67ul of nuclease free water, 1.33ul or the appropriate RT reaction, and 1ul of the appropriate 
PCR primer.  The 96 well plate to perform PCR was sealed with an optical adhesive cover and 
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then pulse centrifuged to spin down the contents and eliminate air bubbles.  To perform PCR, an 







Time   10 min  15 sec  60 sec 
Temp(⁰C)  95  95  60 
 
Statistical Analysis 
 Statistical analysis was preformed on all data using PASW Statistics 17 (formerly SPSS). 
Statistically significant differences in body weights, caloric consumption, as well as all serum 
hormone levels were calculated using paired sample t-tests.  Analysis of the tumor burden 
required the use non-parametric Mann–Whitney U test in order to determine significance.  
Assessment of miRNA expression was carried out utilizing a single sample t-test in which the 
relative quotients of expression was compared to a test value of 0. 
Histopathologic Analysis  
 Formalin-fixed pancreatic tissue from BK5.COX-2 mice were embedded in paraffin and 
cut into 4-um thick sections and processed for hematoxylin and eosin (H&E) staining. The 
percentage of the pancreas comprised of proliferating ducts was determined under low power 
magnification using H&E-stained sections. Metaplastic changes in ducts (metaplasia), cellular 
and nuclear atypia (atypia), degree of inflammatory cell infiltration (inflammation), and relative 
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size of the stroma and level of fibrosis (fibrosis) were scored in a blinded manner by a certified 
veterinary pathologist (M.J.M.) according to the following criteria. 0= normal pancreas, 1= 
minimal (5-10% affected), 2= mild (10-25% affected), 3=moderate (25-50% affected), 4= 
marked (>50% affected). These indices of pathology were also combined to give a composite 




Chapter 3:  Results 
 
Effects of DER on Pancreatic Tumor Growth 
 Following a 7-week diet treatment period that resulted in lean DER mice (mean 
JC101:19.4 ±0.45 g and NB508:19.3±0.057g; Figure 2a,b) relative to control mice (mean JC101: 
27.4+0.75g and NB508: 28.1±0.43g; Figure 2a,b). Mice were injected with either JC101 or 
NB508 pancrearic cancer cell lines and the tumors were followed for four weeks, at which time 
all mice were killed and tumor tissue, blood through a cardiac puncture, and their pancreata were 
collected.  As expected, analysis of tumors collected showed that DER, relative to control diet, 
decreased tumor burden (464.7±101.32 mg in DER versus 964.8±93.21mg in controls, p=0.007; 
Figure 2e) in mice that received JC101 cells.  However, no diet effect was observed in mice 
injected with NB508 cells (239.4±126.65 mg in DER versus 208.5±51 mg in Controls, p=0.48 
Figure 2f). The failure of the NB508 arm of the study is surprising given past successes with the 
cell line in the Hursting lab. Notably the NB508 cells injected did not behave as aggressively as 
they have in past studies when they were othotopically injected into pancreata, which may 
indicate that the cell line is not suitable for a subcutaneous study or requires modifications to the 
protocol, such as the addition of matrigel or higher cell concentrations.  While this warrants 
further investigation, all subsequent studies in this thesis will focus on the JC101 cells, which 




Figure 2: Animal Study Data: Weight, Calorie Consumption, Tumor Burden. A.) Body weight 
for mice that received JC101 cells (p<0.0001). B) Body weight for mice the received NB508 
cells (p<0.0001) C.) kCal consumed for mice that recived JC101cells (p<0.0001) D.) kCal 
consumed for mice that received NB508 (p<0.0001) E.) Tumor Burden for mice with JC101 
cells average weight 964.75±93.21 mg for mice on  control diet and 464.6667±101.32 mg for 
mice on DER (p=0.007)  F.) Tumor Burden for mice with NB508 cells average weight 208.51 
±51 mg for mice on control diet and 239.375±126.65 mg  for mice on DER (p=0.477). 
 
Effects of DER on Serum Hormones and Immunohistochemical Markers  
Further characterization of the effect of of DER in mice that received JC101 cells was 
performed using serum analysis from the terminal bleed and immunohistochemistry on collected 
tumor tissue.  Serum analysis was preformed using Millipore hormone assay kits to assess levels 
of IGF-1, insulin, adiponectin, and leptin. Mice placed on DER showed the expected significant 
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changes in serum levels of insulin, IGF-1, and leptin (Figure 3a,b,c). While serum adiponectin 
levels were not significantly different, they did trend in the expected direction (Figure 3d). 
 
Figure 3: Analysis of serum hormones from mice that received an injection of x105 JC101 cells. 
A.) The average concentration of insulin in the analyzed serum was 0.71 ng/ml in control mice 
and 0.28 ng/ml in DER mice (p= 0.014) B.) IGF-1 was present at a concentration of 67.21 ng/ml 
in control mice and 20.70 ng/ml in DER mice (P < 0.0001). C.) Leptin serum levels were 1.99 
pg/ml in control mice and 0.52 in DER mice (p=0.0005) D.) Adiponectin was only slightly 
lowered in control mice, 8.13 ng/ml, compared to DER mice, 8.89, yielding a non-significant 
difference (P=0.378) that trended in the expected direction. 
 
 Slides were made from paraffin-embedded blocks of tumor tissue and stained for H&E, 
CD31, Ki67, and cleaved caspase 3 in order to assess the general structure and vascularization of 
the tumors as well as assess DER effects on cell division and apoptosis. Analysis of the slides 
shows that DER decreased fibrosis, cellular proliferation, and vascularization in the tumors when 
compared to control tumors, while not affecting the rate of apoptosis (Fig.4). The alterations in 
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the general biology of the tumor in response to DER are consistent with previous findings in the 
Hursting lab in several cancer models. 
 
Figure 4: Immunohistochemistry was preformed on slides prepared from paraffin-
embedded tumor tissue collected from JC101 mice during sacrifice. H&E staining was 
performed to assess the gross pathological features of the tumor, and shows a decrease in fibrosis 
in DER mice when compared to control. CD31 staining was performed to evaluate differences in 
vascularization between control and DER tumors. As seen in the slides imaged there is an 
increase in vascularization in control tumors compared to that seen in DER tumors. Ki-67 and 
Caspase 3 staining were performed to assess rates of cellular proliferation and apoptosis 
respectively. DER tumors displayed a decreased Ki-67 staining indicative of lower rates of 
cellular proliferation while not displaying any change in apoptosis when compared to control 
tumors. All images were captured at 40x magnification.  
Effects of DER on miRNA Expression 
The unexplored nature of the relationships between DER modulation, miRNA 
expression, and tumor burden necessitated a global approach to identify potential miRNA for 
further investigation. Before using a large amount of tumor tissue and funding, we decided to 
perform a pilot to assess the usefulness of the Exiqon array system using tumor and pancreas 
tissue from one control and one DER mouse. Four comparisons were chosen to determine the 
effects of DER (relative to control), as well as the effects of cancer development (versus normal 
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pancreas tissue) on miRNA expression. The two conditions that yielded the largest number of 
differentially expressed miRNA were: Control Tumor v. Control Pancreas and DER Tumor v. 
DER Pancreas. Although limited by the small sample size, these pilot data showing differentially 
expressed miRNAs between tumor and normal pancreas, and between DER and controls, were 
















mmu‐miR‐763  0.0359  0.011  0.008 
hsa‐miR‐452  0.0588  0.012  0.010 
kshv‐miR‐K12‐8  0.0596  0.017  0.013 
hsa‐miR‐221*  0.0597  0.013  0.010 
hsa‐miR‐148a/mmu‐miR‐148a  0.0661  0.010  0.008 
hsa‐miRPlus‐E1053  0.0883  0.011  0.010 
hsa‐miRPlus‐F1193  0.0938  0.426  0.077 
hsa‐miR‐375/mmu‐miR‐375/rno‐miR‐375  0.1054  0.021  0.018 
hsa‐miR‐802/mmu‐miR‐802/rno‐miR‐802  0.1180  0.010  0.009 
rno‐miR‐494  0.1279  0.011  0.010 
hsv1‐miR‐H7*  0.1346  0.008  0.007 
mmu‐miR‐675‐5p/rno‐miR‐675  0.1358  0.017  0.015 
hsa‐miR‐200c/mmu‐miR‐200c/rno‐miR‐200c  0.1424  0.034  0.027 
mcmv‐miR‐m88‐1  0.1497  0.049  0.037 
hsa‐miR‐525‐5p  0.1584  0.032  0.027 
hsa‐miR‐665  0.1703  0.011  0.011 
hsa‐miRPlus‐F1099  0.1875  0.107  0.068 
hsa‐miR‐200b/mmu‐miR‐200b/rno‐miR‐200b  0.1909  0.052  0.041 
hsa‐miR‐200a/mmu‐miR‐200a/rno‐miR‐200a  0.1924  0.058  0.045 
hsa‐miR‐410/mmu‐miR‐410/rno‐miR‐410  0.1969  0.029  0.025 
mmu‐miR‐665/rno‐miR‐665  0.1996  0.045  0.036 
hsa‐miRPlus‐E1093  0.2037  0.031  0.027 
hsa‐miR‐1260  0.2093  0.034  0.029 
hsa‐miR‐1296  0.2131  0.060  0.047 
mmu‐miR‐1900  0.2184  0.021  0.019 
mmu‐miR‐743b‐3p  0.2281  0.053  0.043 
hsa‐miR‐494/mmu‐miR‐494  0.2329  0.011  0.011 
hsa‐miR‐141/mmu‐miR‐141/rno‐miR‐141  0.2373  0.051  0.042 
mmu‐miR‐1934  0.2531  0.037  0.032 
hsa‐miR‐933  0.2562  0.038  0.033 
ebv‐miR‐BHRF1‐1  0.2567  0.039  0.034 
hsa‐miR‐1284  0.2647  0.047  0.040 
mmu‐miR‐2144  0.2705  0.027  0.024 
hsa‐miR‐637  0.2768  0.057  0.047 
hsa‐miR‐675*  0.2850  0.054  0.045 
24 
 
mmu‐miR‐291b‐5p  0.2893  0.046  0.040 
hsa‐miR‐1275  0.2939  0.041  0.036 
mmu‐miR‐300*/rno‐miR‐300‐5p  0.2941  0.018  0.017 
sv40‐miR‐S1‐5p  0.2980  0.030  0.028 
hsa‐miR‐422a  0.3016  0.048  0.041 
mmu‐miR‐291a‐5p/rno‐miR‐291a‐5p  0.3114  0.044  0.038 
hsa‐miRPlus‐E1097  0.3115  0.049  0.042 
mmu‐miR‐2143  0.3119  0.039  0.035 
hsa‐miR‐139‐5p/mmu‐miR‐139‐5p/rno‐miR‐139‐5p  0.3133  0.042  0.037 
mmu‐miR‐207/rno‐miR‐207  0.3155  0.021  0.019 
ebv‐miR‐BART8*  0.3215  0.041  0.036 
hsa‐miRPlus‐F1246  0.3250  0.019  0.018 
mmu‐miR‐762  0.3265  0.092  0.072 
mmu‐miR‐667/rno‐miR‐667  0.3283  0.050  0.044 
hsa‐miR‐519e*  0.3331  0.047  0.042 
hsv1‐miR‐H6  0.3350  0.064  0.054 
mmu‐miR‐2135  0.3384  0.044  0.039 
mmu‐miR‐2146  0.3390  0.022  0.021 
hsa‐miRPlus‐F1240  0.3408  0.304  0.161 
mmu‐miR‐1952  0.3533  0.044  0.039 
hsa‐miRPlus‐E1038  0.3546  0.021  0.020 
hsa‐miRPlus‐E1225  0.3624  0.060  0.051 
hsa‐miR‐29c/mmu‐miR‐29c/rno‐miR‐29c  0.3643  0.051  0.045 
mmu‐miR‐2141  0.3654  0.034  0.031 
hsa‐miR‐1308  0.3665  0.041  0.037 
hsa‐miRPlus‐F1127  0.3670  0.125  0.093 
hsa‐miR‐483‐3p  0.3909  0.039  0.035 
hsa‐miR‐513a‐5p  0.4058  0.038  0.035 
hsa‐miR‐224*  0.4072  0.054  0.048 
hsa‐miR‐152/mmu‐miR‐152/rno‐miR‐152  0.4228  0.039  0.036 
hsa‐miR‐103‐2*  0.4295  0.062  0.054 
hsa‐miRPlus‐E1238  0.4334  0.066  0.057 
hsa‐miR‐551b/mmu‐miR‐551b/rno‐miR‐551b  0.4429  0.038  0.035 
hsa‐miR‐1280  0.4526  0.054  0.048 
hsa‐miRPlus‐E1102  0.4550  0.067  0.058 
hsa‐miR‐1976  0.4551  0.031  0.029 
mghv‐miR‐M1‐4  0.4596  0.032  0.030 
mghv‐miR‐M1‐3  0.4609  0.124  0.098 
hsa‐miR‐1908  0.4679  0.065  0.057 
mmu‐miR‐21*/rno‐miR‐21*  0.4684  0.191  0.136 
mmu‐miR‐2140  0.4759  0.066  0.058 
Table 2 (Continued) 
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hsa‐miR‐187*  0.4780  0.072  0.062 
hsa‐miR‐490‐3p/mmu‐miR‐490/rno‐miR‐490  0.4817  0.053  0.047 
hsa‐miR‐617  0.4833  0.073  0.064 
hsa‐miRPlus‐E1285  0.4846  0.062  0.055 




























































































































mmu‐miR‐466b‐5p  2.8139  0.129  0.1236 


































































hsa‐miR‐99b/mmu‐miR‐99b/rno‐miR‐99b  3.4281  0.346  0.3144 



































































hsa‐miR‐22/mmu‐miR‐22/rno‐miR‐22  5.2350  0.602  0.5405 

























































Table 2: miRNAs differentially expressed in a comparison between tumor and pancreas 
from the same control mouse that received an injection of JC101 cells. Numbers in blue 
represent miRNAs whose expression is lower in tumor than pancreas and orange numbers 














mmu‐miR‐763  0.0498  0.007  0.006 
hsa‐miR‐221*  0.0557  0.009  0.008 
kshv‐miR‐K12‐8  0.0935  0.038  0.027 
mmu‐miR‐452  0.1067  0.008  0.008 
ebv‐miR‐BART2‐3p  0.1179  0.007  0.006 
hsa‐miR‐494/mmu‐miR‐494/rno‐miR‐494  0.1348  0.007  0.007 
hsa‐miR‐30b*  0.1600  0.008  0.008 
hsa‐miR‐200b/mmu‐miR‐200b/rno‐miR‐
200b  0.1721  0.007  0.007 
hsa‐miR‐452  0.1725  0.053  0.041 
hsa‐miR‐802/mmu‐miR‐802/rno‐miR‐802  0.1826  0.028  0.025 
hsa‐miR‐675*  0.1886  0.051  0.040 
hsa‐miR‐200c/mmu‐miR‐200c/rno‐miR‐
200c  0.1914  0.013  0.012 
mmu‐miR‐675‐5p/rno‐miR‐675  0.2382  0.008  0.008 
hsa‐miR‐933  0.2668  0.052  0.043 
hsa‐miR‐148a/mmu‐miR‐148a  0.2925  0.252  0.135 
mmu‐miR‐300*/rno‐miR‐300‐5p  0.3029  0.039  0.035 
mmu‐miR‐291a‐5p/rno‐miR‐291a‐5p  0.3095  0.046  0.040 
sv40‐miR‐S1‐5p  0.3313  0.039  0.035 
mmu‐miR‐291b‐5p  0.3377  0.063  0.053 
hsa‐miR‐921  0.3414  0.035  0.031 
hsa‐miR‐519e*  0.3710  0.029  0.027 
mmu‐miR‐667/rno‐miR‐667  0.3788  0.037  0.033 
hsa‐miR‐520d‐5p  0.4005  0.042  0.038 
mmu‐miR‐325/rno‐miR‐325‐3p  0.4109  0.052  0.046 
hsa‐miRPlus‐C1115 (miRPlus_17952)  0.4171  0.024  0.023 
hsa‐miR‐513a‐5p  0.4191  0.029  0.027 
hsa‐miR‐503  0.4210  0.046  0.041 
mghv‐miR‐M1‐4  0.4307  0.034  0.031 
hsa‐miR‐371‐5p  0.4327  0.031  0.029 
hsa‐miR‐551b/mmu‐miR‐551b/rno‐miR‐
551b  0.4386  0.042  0.038 
hsa‐miR‐193a‐5p  0.4457  0.028  0.026 
mmu‐miR‐294*/rno‐miR‐294  0.4513  0.048  0.043 
hsa‐miR‐149*  0.4516  0.052  0.047 
hsa‐miR‐1908  0.4530  0.073  0.063 
hsa‐miR‐617  0.4537  0.026  0.024 
mmu‐miR‐351/rno‐miR‐351  0.4559  0.033  0.031 




ebv‐miR‐BART8*  0.4847  0.021  0.020 
hsa‐miR‐338‐5p/mmu‐miR‐338‐5p/rno‐
miR‐338*  0.4929  0.190  0.137 
hsa‐miR‐665  0.4959  0.045  0.042 
hsa‐miR‐140‐3p/mmu‐miR‐140*/rno‐miR‐
140*  2.0269  0.380  0.320 
hsa‐miR‐574‐5p/mmu‐miR‐574‐5p  2.0352  0.167  0.155 
mmu‐miR‐466d‐5p  2.1196  0.033  0.032 
mmu‐miR‐690  2.1412  0.321  0.279 
hsa‐miR‐550  2.1695  0.072  0.070 
hsa‐miR‐26b/mmu‐miR‐26b/rno‐miR‐26b  2.2153  0.055  0.054 
hsa‐miR‐26a/mmu‐miR‐26a/rno‐miR‐26a  2.4059  0.247  0.224 
hsa‐miR‐146b‐5p/mmu‐miR‐146b/rno‐miR‐
146b  2.4453  0.512  0.423 
hsa_SNORD3@  2.4466  0.211  0.194 
mmu‐miR‐674/rno‐miR‐674‐5p  2.4734  0.646  0.512 
hsa‐miR‐27a/mmu‐miR‐27a/rno‐miR‐27a  2.4786  0.687  0.538 
mmu‐miR‐706  2.4829  0.131  0.125 
mmu‐let‐7i/rno‐let‐7i  2.5771  0.492  0.413 
hsa_SNORD2  2.5997  0.143  0.136 
mmu‐let‐7g  2.6195  1.318  0.877 
hsa‐miR‐32*  2.6377  0.119  0.114 
hsa‐miR‐20a/mmu‐miR‐20a/rno‐miR‐20a  2.7642  0.198  0.185 
hsa‐miR‐106b/mmu‐miR‐106b/rno‐miR‐
106b  2.8863  0.549  0.461 
mmu‐let‐7f/rno‐let‐7f  2.9447  2.522  1.358 
hsa‐let‐7i/mmu‐let‐7i/rno‐let‐7i  2.9875  0.456  0.396 
hsa‐miR‐27b/mmu‐miR‐27b/rno‐miR‐27b  3.0282  0.185  0.174 
hsa‐let‐7a/mmu‐let‐7a/rno‐let‐7a  3.3296  0.375  0.337 
hsa‐miR‐302d*  3.3680  0.178  0.169 
mmu‐miR‐691  3.3778  0.796  0.644 
hsa‐miR‐99b/mmu‐miR‐99b/rno‐miR‐99b  3.5258  0.532  0.462 
hsa‐miR‐199a‐5p/mmu‐miR‐199a‐5p/rno‐
miR‐199a‐5p  3.7414  0.340  0.311 
hsa‐miR‐130a/mmu‐miR‐130a/rno‐miR‐
130a  3.7579  0.452  0.403 
hsa‐miR‐191/mmu‐miR‐191/rno‐miR‐191  3.8539  0.151  0.145 
mmu‐let‐7d/rno‐let‐7d  3.8730  0.324  0.299 
hsa‐miR‐29a/mmu‐miR‐29a/rno‐miR‐29a  4.0693  0.674  0.578 
hsa‐miR‐222/mmu‐miR‐222/rno‐miR‐222  4.1035  1.502  1.099 
hsa‐miR‐223/mmu‐miR‐223/rno‐miR‐223  4.2059  0.688  0.591 
hsa‐let‐7c/mmu‐let‐7c/rno‐let‐7c  4.3136  0.274  0.258 
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hsa‐miR‐129*  4.6160  0.311  0.291 
hsa‐miRPlus‐A1083 (miRPlus_42856)  4.6939  0.401  0.369 
hsa‐miR‐133a/mmu‐miR‐133a/rno‐miR‐
133a  4.7570  0.260  0.247 
hsa‐let‐7b/mmu‐let‐7b/rno‐let‐7b  4.9793  0.474  0.433 
hsa‐miR‐133b/mmu‐miR‐133b/rno‐miR‐
133b  4.9808  0.536  0.484 
hsa‐miR‐22/mmu‐miR‐22/rno‐miR‐22  5.1922  0.219  0.210 
hsa‐miR‐214/mmu‐miR‐214/rno‐miR‐214  5.1967  0.486  0.444 
hsa‐miR‐15b/mmu‐miR‐15b/rno‐miR‐15b  5.5191  0.659  0.589 
hsa‐miR‐16/mmu‐miR‐16/rno‐miR‐16  5.5351  0.871  0.752 
mmu‐miR‐709  5.6932  1.165  0.967 
hsa‐let‐7e/mmu‐let‐7e/rno‐let‐7e  5.8241  0.298  0.283 
hsa‐miR‐23a/mmu‐miR‐23a/rno‐miR‐23a  5.8662  0.479  0.443 
hsa‐miR‐125a‐5p/mmu‐miR‐125a‐5p/rno‐
miR‐125a‐5p  6.1261  0.333  0.316 
hsa‐miR‐23b/mmu‐miR‐23b/rno‐miR‐23b  6.1373  5.119  2.791 
hsa‐miR‐31/mmu‐miR‐31/rno‐miR‐31  6.5310  0.282  0.271 
hsa‐miR‐1/mmu‐miR‐1  6.5549  1.016  0.880 
hsa‐miR‐129‐3p/mmu‐miR‐129‐3p/rno‐
miR‐129*  6.7539  0.738  0.665 
hsa‐miR‐24/mmu‐miR‐24/rno‐miR‐24  7.6734  1.152  1.001 
hsa‐miR‐21/mmu‐miR‐21/rno‐miR‐21  15.3540  2.181  1.910 
hsa‐miR‐125b/mmu‐miR‐125b‐5p/rno‐miR‐
125b‐5p  25.1075  8.347  6.265 
Table 3: miRNAs differentially expressed in a comparison between tumor and pancreas 
from the same DER mouse that received an injection of JC101 cells. Numbers in blue represent 
miRNAs whose expression is lower in tumor than pancreas and orange numbers represent 
miRNAs whose expression is increased in the tumor compared to the pancreas.  
 
Altered miRNA expression found in a comparison of DER pancreas and control pancreas 
yielded fewer miRNAs with altered expression (Table 4) than were seen in the cancer versus 
normal tissue described above. However, among the altered miRNAs were mir-155, 216, and 
217 all of which have previously been identified in miRNA profiles of pancreatic cancer derived 
from paraffin-embedded human tissues. Of particular interest is mir-155, whose overexpression 
is associated with the early stages of pancreatic carcinogenesis [15].  Increased expression of 
mir-216 and -217 have been associated with increased survivability in human pancreatic cancer 
Table 3 (Continued) 
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cases when found with a lower expression of mir-196 [16]. Though mir-196 was not seen to be 
altered in our pilot study, a follow up on the importance of this expression profile is warranted.  
Surprisingly, the comparison of DER tumor and control tumor in our follow-up study (n=3/diet) 
yielded the fewest differentially expressed miRNAs (Table 5). However, it is important to note 
that all three miRNA identified in the follow-up study also appeared in the pilot study.  
 
miRNA 






hsa‐miR‐422a  0.420105971  0.038  0.035 
hsa‐miR‐155  0.420193555  0.070  0.060 
hsa‐miR‐1308  0.425156062  0.016  0.016 
hsa‐miRPlus‐E1038  0.436275487  0.047  0.043 
ebv‐miR‐BART6‐3p  0.438015899  0.039  0.035 
mmu‐miR‐2146  0.46530473  0.052  0.047 
hsa‐miR‐217/mmu‐miR‐
217/rno‐miR‐217  2.013822449  0.244  0.217 
hsa‐miRPlus‐F1246  2.380355076  0.281  0.251 
hsa‐miR‐216b/mmu‐miR‐
216b  2.568190459  0.650  0.519 
Table 4: miRNAs differentially expressed in a comparison between DER and control 
pancreas from mice that received an injection of JC101 cells. Numbers in blue represent 
miRNAs whose expression is lower in DER pancreas when compared to control pancreas and 




miRNA Relative Quant (Tumor DER/Tumor Control) Pos Error Neg Error 
mmu‐miR‐2135  0.40967635  0.033  0.031 
mmu‐miR‐2146  0.433223198  0.031  0.029 
mmu‐miR‐669c  0.491028809  0.108  0.089 
Table 5: miRNAs differentially expressed in a comparison between DER and control 
tumor from mice that received an injection of JC101 cells. Numbers in blue represent miRNAs 






In light of the ability of the Exiqon array system to successfully detect altered miRNA 
expression,  JC101 tumors that from  DER (n=3) and control (n=3)  mice were paired and had 
their total RNA extracted  and miRNA expression analyzed as described above.  Though a 
variable number of miRNA were expressed in each sample (Appendix), three miRNA had their 
expression consistently decreased in the DER tumors when compared to control tumors, though 
only mir-669c has a known function (Fig.5). Interestingly, mir-669c has been shown in a number 
of studies to increase as a mouse ages and targets several classes of glutathione S-transferases, 
including Mgst1. Given the relationship between DER and an increased life span seen in studies, 
the role that mir-669c is playing in the tumor system warrants further investigation[17].  
 
Figure 5: Effects of DER on miRNA expression in JC101 Tumors. Exiqon miRNA arrays were 
performed on three sets of matched DER and control tumors. Analysis of the data showed that 3 
miRNA were consistently down regulated compared to control. Expression of miRNA-669c was 
reduce by an average of 61% compared to control (p=0.031). Expression of mir-2135 was 
reduced by an average of 53% of compared to control (p=0.039). Expression of mir-2146 was 




Further investigation of miRNA will utilize TaqMan MicroRNA Reverse Transcription 
Kit and Taqman miRNA Probes (Applied Biosystems).   However, before proceeding with RT-
PCR for miRNA one must determine the appropriate control to use. Based on literature searches 
mir-16 and snU6 were selected for evaluation in a series of serum starvation and IGF-1 treatment 
experiments with Panc02 cells. Upon analysis of the data mir-16 appears to be more stably 
expressed than snU6 (Table 6) and thus will be selected for use as a control in future qPCR 
experiments. 
 
Table 6:  Determination of control for RT-PCR of miRNA. RT-PCR was performed to 
screen for a control for future work with miRNA.  Mir-16 was determined to be a more 






Chapter 4: Discussion and Future Directions 
 Expanding our understanding of the mechanisms by which DER hinders pancreatic 
cancer growth and progression has the potential to provide insights into combating the disease. 
Here we show the feasibility of a subcutaneous syngeneic transplant of JC101 cells in FVB mice.  
Consistent with previous findings from our lab and others, DER suppressed JC101 pancreatic 
tumor growth, decreased serum levels of several hormones and growth factors linking 
metabolism and cell growth, and decreased cell proliferation, fibrosis and vascularization of the 
tumors[8, 10, 18, 19].   These findings suggest that this is a valid model for further exploring the 
mechanisms underlying the effects of DER on pancreatic tumor growth, including miRNA 
analyses.  
In contrast, we found no effect of DER on NB508 tumor growth.  Surprisingly, 
subcutaneous tumor growth following transplantation of these cells, which are driven by 
overexpression K-ras in combination with INK-4A deficiency, was much less than that observed 
with JC101 cells.  It is possible that more robust tumor growth with these cells requires a higher 
cell concentration, longer follow-up, or the presence of support materials, such as the use of 
matrigel.  Given the importance of K-ras mutations in human pancreatic cancer, additional 
experiments are warranted with these NB508 cells to determine what conditions, if any, are 
required to optimize tumor growth following subcutaneous transplantation.  However, such 
studies are beyond the scope of this thesis, and all subsequent analyses will focus on the JC101 
cells, which display a robust tumor response that is suppressed by DER. 
 To explore the potential role of miRNA in the effects of DER on JC101 tumor growth, 
array data were obtained from matched tumor tissue using the Exiqon array platform.  This 
analysis revealed that three miRNAs were consistently down regulated by DER; mir-669c, mir-
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2135, and mir-2146. Only mir-669c has been previously identified, with mir-2135 and 2146 
being computer predicted miRNAs, with no known function at present. The down regulation of 
mir-669c by DER is of great interest in light of its known role in regulating translation of 
glutathione-s transferase (GST) [20]. GSTs are a family of enzymes composed of many 
cytosolic, mitochondrial, and microsomal proteins that act as catalysts for many important 
cellular reactions linked to aging and cancer.  They as also impact the metabolism of many 
endogenous and xenobiotic substrates[21]. Given the wide range or roles that GSTs play in the 
body, including detoxification, oxidative stress, protein transport,  it is not surprising that GSTs 
have been shown to play a role in carcinogenesis[20]. With respect to pancreatic cancer, a recent 
epidemiological study found that mutations in GST increased the odds ratio of pancreatic cancer 
occurring in a patient to 1.38-2.50 depending on the mutation[22]. The known functionality of 
mir-669c as a regulator of GST’s, combined with the observation that mir-669c expression 
increases with age (a key risk factor for pancreatic cancer) suggests that this miRNA may play an 
important role in carcinogenesis [5, 17].  Though substantial work has been reported concerning 
GST’s and related pathways in cancer, no prior studies have shown  connections between energy 
balance, microRNAs,(including mr669c), and pancreatic cancer.  
 Despite the obvious limitations inherent in the small sample size, the data obtained from 
my initial pilot to assess the usefulness of the Exiqon array platform also warrants further 
analyses.  Comparisons between control tumor and pancreas, as well DER tumor and pancreas, 
yielded a large number of differentially expressed miRNA that need extensive follow up work in 
order to identify possible avenues for future research that may have relevance to diet and 
pancreatic cancer prevention.  The analysis of differential miRNA expression between DER and 
control pancreas yielded a small profile with three interesting results. Mir-155 overexpression is 
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thought to be an important early step in pancreatic carcinogenesis, with upwards of 80% of 
patients displaying overexpression in this miRNA[15]. Giving the role, that upregulation of mir-
155 plays in early carcinogenesis it is of note that the pancreas from the DER-treated mouse had 
a decreased expression of mir-155 compared to control. If confirmed in larger studies, regulation 
of mir-155 in normal pancreas may be a means by which energy balance modifies risk for 
pancreatic cancer in patients. Also of note is the upregulation of mir- 216 and 217 by DER in 
pancreas when compared to control. Mir-216 and 217 are often used as an indicator of prognosis 
in combination with mir-196a. In general an increase in expression of mir-196a and a decrease in 
the expression of mir-216 and 217 is associated with a poor prognosis[16]. However, mir-196a 
did not appear to be differentially regulated, and the increase in mir-216 and 217 expression may 
be indicative of calorie restriction lending itself to a better prognosis.  It is important to note 
however, that findings involving mir-155, -216, and -217 are at best preliminary at this time 
given the sample size of one. Further evaluation of the state of the miRNAs in normal and DER 
pancreas is necessary to determine if these results occur consistently, and thus warrant further 
research.  
 Given the global effects of DER we were surprised by the small number of miRNA that 
were differentially regulated in matched tumor tissue.  The most likely explanation for the 
phenomena is that the JC101 cell transplant model is not ideal for determining the relationship 
between DER, cancer, and miRNA.  Many studies have shown that miRNA alteration occurs 
early in the tumorigenesis process rather than later[23]. Therefore, the use of transformed cells 
with a large number of pre-existing mutations may have hindered DER’s ability to alter miRNA 
expression. The best way to assess this hypothesis is to use a transgenic model with tissue 
collection at multiple timepoints, allowing a comparison of miRNA expression over time. A 
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better understanding of the timeline of differential miRNA expression in pancreatic cancer has 
the potential to elucidate new targets for diagnostic tests as well lead to the development of more 
















Name Relative Quant (Control/DER  ) Pos. Error Neg. Error 
mmu-miR-106a 0.416 0.086 0.072 
mmu-miR-101a 0.422 0.085 0.071 
mmu-miR-30d 0.436 0.077 0.065 
mmu-miR-301a 0.438 0.071 0.061 
mmu-miR-140* 0.461 0.205 0.142 
mmu-miR-191 0.486 0.041 0.038 
mmu-miR-195 0.487 0.038 0.035 
mmu-miR-24 0.489 0.020 0.020 
mmu-miR-210 0.498 0.043 0.039 
hsa-miRPlus-E1151 2.030 0.254 0.226 
mmu-miR-691 2.032 0.258 0.229 
mmu-miR-709 2.060 0.086 0.083 
hsa-miR-32* 2.076 0.382 0.323 
hsa-miR-765 2.102 0.314 0.273 
hsa-miR-149* 2.140 0.309 0.270 
hsa-miR-617 2.149 0.089 0.085 
mmu-miR-669n 2.207 0.235 0.212 
mmu-miR-466d-5p 2.232 0.125 0.119 
hsa-miRPlus-F1225 2.245 0.230 0.208 
hsa-miRPlus-E1212 2.289 0.275 0.246 
mmu-miR-1196 2.384 0.075 0.073 
mmu-miR-1897-5p 2.410 0.279 0.250 
mmu-miR-669c 2.505 0.293 0.262 
mmu-miR-300* 2.604 0.255 0.232 
hsa-miR-422a 2.909 0.404 0.355 
mmu-miR-2135 3.008 0.322 0.291 
hsa-miRPlus-F1193 3.282 0.336 0.305 






Name Relative Quant (Control/DER ) Pos. Error Neg. Error 
mmu-miR-21 0.346 0.029 0.027 
mmu-miR-19b 0.362 0.052 0.045 
mmu-miR-222 0.376 0.030 0.028 
mmu-miR-130a 0.385 0.042 0.038 
mmu-miR-31* 0.390 0.024 0.023 
mmu-miR-29b 0.397 0.040 0.037 
mmu-miR-193 0.414 0.062 0.054 
mmu-miR-155 0.426 0.068 0.059 
mmu-miR-106a 0.449 0.037 0.034 
mmu-miR-31 0.452 0.061 0.054 
mmu-miR-210 0.454 0.071 0.061 
hsa-miR-1979 0.474 0.032 0.030 
mmu-miR-301a 0.480 0.039 0.036 
mmu-miR-221 0.481 0.031 0.029 
mmu-miR-20a 0.491 0.032 0.030 
mmu-miR-23a 0.498 0.026 0.025 
hsa-miR-1299 2.051 0.211 0.191 
mmu-miR-468 2.101 0.159 0.148 
hsa-miRPlus-F1225 2.115 0.068 0.065 
mmu-miR-378 2.128 0.160 0.149 
mmu-miR-2146 2.170 0.284 0.251 
hsa-miRPlus-E1151 2.174 0.165 0.153 
hsa-miR-422a 2.215 0.344 0.298 
hsa-miRPlus-F1193 2.233 0.301 0.266 
mmu-miR-467h 2.238 0.192 0.177 
mmu-miR-883a-5p 2.276 0.269 0.240 
mmu-miR-300* 2.304 0.256 0.231 
mmu-miR-1897-5p 2.319 0.244 0.221 
hsa-miRPlus-E1200 2.391 0.073 0.070 
mmu-miR-466f-5p 2.393 0.314 0.278 
mmu-miR-466e-5p 2.454 0.297 0.265 
mmu-miR-1187 2.482 0.122 0.116 
rno-miR-466c 2.532 0.498 0.416 
mmu-miR-2135 2.619 0.135 0.128 
mmu-miR-669l 2.627 0.236 0.216 
mmu-miR-466b-5p 2.670 0.158 0.149 
mmu-miR-466a-5p 2.763 0.163 0.154 
mmu-miR-669e 2.778 0.119 0.114 
mmu-miR-669n 2.803 0.151 0.143 
hsa-miR-32* 2.808 0.191 0.179 
mmu-miR-669o 2.876 0.187 0.176 
mmu-miR-574-5p 2.878 0.315 0.284 
rno-miR-466b 2.987 0.319 0.288 
mmu-miR-466c-5p 3.073 0.387 0.343 
mmu-miR-466d-5p 3.246 0.590 0.499 
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hsa-miRPlus-E1212 3.346 0.599 0.508 
mmu-miR-669c 3.669 0.290 0.269 
mmu-miR-133a 3.706 0.306 0.283 
mmu-miR-1 4.962 0.740 0.644 
mmu-miR-133b 6.894 0.448 0.421 










Name Relative Quant (Control/DER) Pos. Error Neg. Error 
hsa-miR-491-3p 0.480 0.085 0.072 
hsa-miRPlus-F1193 2.003 0.259 0.230 
hsa-miR-422a 2.013 0.223 0.201 
mmu-miR-669c 2.016 0.203 0.184 
mmu-miR-466d-5p 2.016 0.707 0.523 
mmu-miR-720 2.031 0.102 0.098 
mmu-miR-2132 2.232 0.152 0.143 
mmu-miR-2138 3.203 0.182 0.172 
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